Improving outcomes for people with advanced immunological diseases.
Location: Switzerland
Total raised: $400M
Investors 1
| Date | Name | Website |
| 01.07.2025 | Omega Fund... | omegafunds... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.01.2026 | Series A | $200M | - |
| 13.01.2025 | Series A | $200M | - |
Mentions in press and media 17
| Date | Title | Description |
| 30.03.2026 | Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year | TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximat... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 24.03.2026 | KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF | Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. R&D Expenses was approximately RMB1319.68 million. Loss for the period was RMB381... |
| 16.01.2026 | Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference | CHENGDU, China, Jan. 16, 2026 /PRNewswire/ -- From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmace... |
| 12.01.2026 | Switzerland's Biotech Surge: Windward Bio Secures Funding, Forges Global Drug Deal Amidst Venturelab's Record Year | Swiss innovation is surging. Venturelab, a key accelerator, empowered over 6,700 entrepreneurs in 2025. It propelled Swiss startups to raise billions in funding. Biotech leader Windward Bio exemplified this success. The company secured a si... |
| 06.01.2026 | Windward Bio signs new licensing agreement to expand clinical pipeline | Windward Bio, a clinical-stage biotechnology company, launched in early 2025 with a $200M Series A led by top-tier investors. The company is building a pipeline of long-acting bispecific antibodies, targeting validated biology in respirato... |
| 23.12.2025 | Venturelab 2025: Powering Over 6,700 Entrepreneurs | 23.12.2025 13:40, Rita Longobardi 2025 was a record-breaking year for Venturelab, delivering 544 days of training, workshops, and international programs to 6,700 entrepreneurs and driving Swiss startups to raise billions. From Venture Kick ... |
| 23.07.2025 | HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma | Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TS... |
| 23.07.2025 | Kelun-Biotech's Partner Windward Bio Announces Initiation of a Global Phase 2 Asthma Trial of SKB378/WIN378 | CHENGDU, China, July 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", HKEX: 6990) today announced that its partner, Windward Bio AG ("Windward Bio") ... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
Show more